LEADER 03411nam  22006735  450 
001 9910298607603321
005 20200705123307.0
010   $a3-319-89878-7
024 7 $a10.1007/978-3-319-89878-0
035   $a(CKB)4100000004823264
035   $a(DE-He213)978-3-319-89878-0
035   $a(MiAaPQ)EBC5407661
035   $a(PPN)229495931
035   $a(EXLCZ)994100000004823264
100   $a20180601d2018      u|         0
101 0 $aeng
135   $aurnn|008mamaa
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aNanooncology $eEngineering nanomaterials for cancer therapy and diagnosis /$fedited by Gil Gonçalves, Gerard Tobias
205   $a1st ed. 2018.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2018.
215   $a1 online resource (VI, 455 p. 156 illus., 106 illus. in color.) 
225 1 $aNanomedicine and Nanotoxicology,$x2194-0452
311   $a3-319-89877-9 
327   $aLiposomes -- Gold nanoparticles -- Quantum Dots -- Fullerenes -- Polymeric nanoparticles -- Silica nanoparticles -- Micelles -- Magnetic nanoparticles -- Dendrimers -- Protein-based nanoparticles -- Carbon Nanotubes.
330   $aThis book presents a systematic overview of the most relevant nanomaterials and their respective intrinsic properties that have been highly explored by the scientific community and pharmaceutical companies in several different modalities for cancer therapy and bioimaging. The chapters explore the synergistic effects provided by the different nanostructured materials and highlight the main in vitro and in vivo therapeutic achievements on cancer. This work also provides relevant discussion about the recent progresses and future challenges that nanotechnology faces on the conception of more efficient nanoformulations against primary tumors, circulating cancer cells and metastases.
410  0$aNanomedicine and Nanotoxicology,$x2194-0452
606   $aNanotechnology
606   $aBiomedical engineering
606   $aCancer research
606   $aBiomaterials
606   $aPharmacology
606   $aNanotechnology$3https://scigraph.springernature.com/ontologies/product-market-codes/Z14000
606   $aBiomedical Engineering and Bioengineering$3https://scigraph.springernature.com/ontologies/product-market-codes/T2700X
606   $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001
606   $aBiomaterials$3https://scigraph.springernature.com/ontologies/product-market-codes/Z13000
606   $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007
615  0$aNanotechnology.
615  0$aBiomedical engineering.
615  0$aCancer research.
615  0$aBiomaterials.
615  0$aPharmacology.
615 14$aNanotechnology.
615 24$aBiomedical Engineering and Bioengineering.
615 24$aCancer Research.
615 24$aBiomaterials.
615 24$aPharmacology/Toxicology.
676   $a616.994
702   $aGonçalves$b Gil$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aTobias$b Gerard$4edt$4http://id.loc.gov/vocabulary/relators/edt
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910298607603321
996   $aNanooncology$91566627
997   $aUNINA